Evidence map›Paper›PMID 35398354›Full record

ArticleThe Journal of biological chemistry2022

The molecular basis of spinocerebellar ataxia type 48 caused by a de novo mutation in the ubiquitin ligase CHIP.

A Umano, K Fang, Z Qu, J B Scaglione, S Altinok, C J Treadway, E T Wick, E Paulakonis, C Karunanayake, S Chou and 7 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

A UmanoDepartment of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA.
K FangDepartment of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA.
Z QuDepartment of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA.
J B ScaglioneDepartment of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA.
S AltinokDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
C J TreadwayDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
E T WickDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
E PaulakonisDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
C KarunanayakeDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
S ChouDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
T M BardakjianDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
P Gonzalez-AlegreDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
R C PageDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
J C SchislerDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
N G BrownDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
D YanDepartment of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA.
K M ScaglioneDepartment of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA; Department of Neurology, Duke University, Durham, North Carolina, USA; Duke Center for Neurodegeneration and Neurotherapeutics, Duke University, Durham, North Carolina, USA. Electronic address: matt.scaglione@duke.edu.
Duke University · USUniversity of North Carolina at Chapel Hill · USMiami University · USUniversity of Pennsylvania · USMedical College of Wisconsin · US

Funding

Medical Scientist Training ProgramT32GM080202 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI BARBIERI, JOSEPH T, SALZMAN, NITA H · 2010 to 2024
$5.7M
Investigation into protein quality control pathways in Dictyostetlium discoideumR35GM119544 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI Kenneth Matthew Scaglione · 2016 to 2026
$4.2M
Spindle Assembly Checkpoint SilencingR35GM128855 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Nicholas Gene Brown · 2018 to 2026
$4.1M
Dual CHIP Functions Control Tau Triage In Alzheimer's DiseaseR01AG061188 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COHEN, TODD JONATHAN, SCHISLER, JONATHAN C. · 2019 to 2023
$3.1M
Triage mechanisms for directing protein refolding and degradationR35GM128595 · NIGMS · MIAMI UNIVERSITY OXFORD · PI Richard C Page · 2018 to 2026
$2.8M
Protein quality control in age-related diseasesR01AG066710 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SCHISLER, JONATHAN C. · 2020 to 2024
$2.4M
Novel chaperones and neurodegenerationR01NS112191 · NINDS · DUKE UNIVERSITY · PI SCAGLIONE, KENNETH MATTHEW · 2019 to 2023
$2.4M
NIA NIH HHS R01 AG061188NIA NIH HHS R01 AG066710NIGMS NIH HHS R35 GM119544NIGMS NIH HHS R35 GM128595NIGMS NIH HHS R35 GM128855NIGMS NIH HHS T32 GM080202NINDS NIH HHS R01 NS112191
6 · The paper itself

Abstract

The spinocerebellar ataxias (SCAs) are a class of incurable diseases characterized by degeneration of the cerebellum that results in movement disorder. Recently, a new heritable form of SCA, spinocerebellar ataxia type 48 (SCA48), was attributed to dominant mutations in STIP1 homology and U box-containing 1 (STUB1); however, little is known about how these mutations cause SCA48. STUB1 encodes for the protein C terminus of Hsc70 interacting protein (CHIP), an E3 ubiquitin ligase. CHIP is known to regulate proteostasis by recruiting chaperones via a N-terminal tetratricopeptide repeat domain and recruiting E2 ubiquitin-conjugating enzymes via a C-terminal U-box domain. These interactions allow CHIP to mediate the ubiquitination of chaperone-bound, misfolded proteins to promote their degradation via the proteasome. Here we have identified a novel, de novo mutation in STUB1 in a patient with SCA48 encoding for an A52G point mutation in the tetratricopeptide repeat domain of CHIP. Utilizing an array of biophysical, biochemical, and cellular assays, we demonstrate that the CHIP

Indexed as

Spinocerebellar AtaxiasUbiquitinUbiquitin-Protein LigasesHumansMutationUbiquitinationSTUB1 protein, humanUbiquitinUbiquitin-Protein LigasesataxiachaperoneE3 ubiquitin ligaseneurodegenerationneurodegenerative disease

Identifiers

PMID35398354
PMCPMC9097460
OpenAlexW4223517877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.